Objective: To investigate the efficacy and tolerability of high-dose N-acetylcysteine (NAC) in the treatment of patients with exacerbations of chronic obstructive pulmonary disease (COPD).

Chronic obstructive pulmonary disease ... This article reviews the current literature related to the treatment of COPD exacerbations and examines whether these data support current treatment ...

Explore strategies for controlling COPD and improving health, with a focus on management and lifestyle changes.

Tezepelumab did not significantly decrease moderate or severe COPD exacerbations compared with placebo, the COURSE trial found.

Among patients with COPD who experienced an exacerbation, the risk for cardiovascular events was highest in the following 2 weeks and stayed elevated more than 1 year after, according to study results ...

If these trials confirm the findings, benralizumab could become the first new therapy approved for eosinophilic exacerbations ...

The following is a summary of “Treating eosinophilic exacerbations of asthma and COPD with benralizumab (ABRA): a ...

After waking up from the procedure, he told me he could take full breaths for the first time in years,” Dr. Mark Sigler said ...

As contemporary surgical practice continues to evolve, patients who undergo surgical lung volume reduction (LVRS) for ...

Ohtuvayre showed significant improvement in lung function by 12 weeks. Follow-up analyses showed that Ohtuvayre had long-term ...

AstraZeneca’s respiratory and immunology portfolio is driving significant growth, with R&I assets forecasted to account for ...